Eating More Vegetables and Fruits and Less Meat May Help Prevent Breast Cancer

Publication
Article
OncologyONCOLOGY Vol 12 No 7
Volume 12
Issue 7

Women who adhere to a low-fat diet with plenty of vegetables and fruits may decrease their risk of developing breast cancer, according to a new study published in the May 1998 issue of The Journal of the American Dietetic Association. The study

Women who adhere to a low-fat diet with plenty of vegetables and fruits may decrease their risk of developing breast cancer, according to a new study published in the May 1998 issue of The Journal of the American Dietetic Association. The study examined the relationship between consumption of specific foods--namely meats, vegetables, and fruits--and levels of oxidative DNA damage in women following their own usual diet or a diet low in fat. The 21 women who participated in the study were healthy but had an increased risk for breast cancer because they had a close relative with breast cancer.

Healthy Diet Repairs Damaged DNA

"Everyone has damaged DNA from which cancer can potentially develop," said Cyndi Thomson, RD, American Dietetic Association spokesperson and researcher at the University of Arizona’s Cancer Center in Tucson. "The question is whether or not a healthier diet can reduce or repair the damaged DNA levels," she added. "This study shows that eating more vegetables and fruits while eating meats in moderation has a positive effect."

The most significant reductions in DNA damage levels were associated with increased consumption of vegetables. Specifically, women who ate more vegetables, especially cooked vegetables, had lower DNA damage levels, while those who ate more beef and pork had higher DNA damage levels.

Although these results are preliminary, they reinforce what nutrition experts have been saying all along. Ms. Thomson notes the need for more research and says, "Diet is not the be-all or end-all cure for cancer, but it is one step Americans can take against cancer. They can eat more vegetables to improve the repair of damaged DNA in their bodies."

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content